BDMAI

Infinite Right-to-Left Scrolling Marquee
Latest Circulars

Sectoral Plan for Effective Logistics – Pharma Sector

BDMAI News Letter – Material contribution by Members

Interaction with USP, India team with our Member companies on 9.1.2025 at 2.00 p.m.

Pharma MSME Industry Meet – 24.1.2025

Delays in obtaining URN / Permission for Destruction of Controlled Substances from NCB

MOU Signing Ceremony between BDMAI and Telangana Council of Higher Education

Implementation of Schedule M – Online Demo by CDSCO for filling application on 14th February 2025

Allotment of land in Green Pharma City, Telangana

Launch of a Scheme for Promotion of Research & Innovation in Pharma MedTech (PRIP) Sector by Department of Pharmaceuticals, Govt. of India

New Guidelines for obtaining NoC for Export of Unapproved/Approved New Drugs

Free In-House Up-Skilling Programme by LSSSDC for Employees BDMAI Member companies

ICH Guidelines- Q7- Telugu Translated version

Special offer by Avila International – Travel Package – CPhI China

Online Application for implementation of Schedule M

Sectoral Plan for Effective Logistics – Pharma Sector

BDMAI News Letter – Material contribution by Members

Interaction with USP, India team with our Member companies on 9.1.2025 at 2.00 p.m.

Pharma MSME Industry Meet – 24.1.2025

Delays in obtaining URN / Permission for Destruction of Controlled Substances from NCB

MOU Signing Ceremony between BDMAI and Telangana Council of Higher Education

Implementation of Schedule M – Online Demo by CDSCO for filling application on 14th February 2025

Allotment of land in Green Pharma City, Telangana

Launch of a Scheme for Promotion of Research & Innovation in Pharma MedTech (PRIP) Sector by Department of Pharmaceuticals, Govt. of India

New Guidelines for obtaining NoC for Export of Unapproved/Approved New Drugs

Free In-House Up-Skilling Programme by LSSSDC for Employees BDMAI Member companies

ICH Guidelines- Q7- Telugu Translated version

Special offer by Avila International – Travel Package – CPhI China

Online Application for implementation of Schedule M

Regulatory Agency

Authority Name of Regulatory Agency Nos.
USA
No: of Sites(Bulk drugs + Formulations) Registered with US FDA (as on 15th april20l 5)
238
No: of Sites(Bulk drugs + Formulations) Registered with US FDA (as on 15th april20l 5)
605
Total No Of DMFs (Type II Active) filed from India (as on 31 St Dec 2019
3820
ANDAs(Ason Feb2016)
3470
EUROPE
Formulation companies withUSFDA approvals.
53
Number of CEPs received (as of February 2016)
1354
Number of companies with CEPs
220
Number of Molecules for which CEPs have been filed with EDQM
382
No of Sites with EU GMP Compliance as on 1 5thFebruary 2016
631
UK MHRA (Medicines Healthcare Regulatory Agency), Market authorizations as on March 2015
1559
Number of CEPs with Irish Medicines Board
300
Number of companies registered in Irish Medicines Board
19
Number of Authorisations with Sweden MPA (Lakemedelsverket)
209
Number of companies having MA s with Sweden MPA (Lafcemedelsverket)
14
WHOGMP
WHO GMP Certified Plants (as per Drug Controller General of India)
1400
Ethiopia
DACA (Drug Administration and Control Authority), Ethiopia (companies)
50
Tanzania
(TFDA) Tanzania Food and Drugs Authority (companies)
1373

© 2021 Templately copyright all right reserved